Compare EEX & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEX | RGNX |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | 371 |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 880.2M | 418.1M |
| IPO Year | N/A | 2015 |
| Metric | EEX | RGNX |
|---|---|---|
| Price | $4.59 | $8.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $7.70 | ★ $28.75 |
| AVG Volume (30 Days) | 26.1K | ★ 776.7K |
| Earning Date | 03-13-2026 | 03-05-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | $7.49 | $50.05 |
| Revenue Next Year | $6.81 | $23.31 |
| P/E Ratio | $236.96 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $3.22 | $5.04 |
| 52 Week High | $5.45 | $16.19 |
| Indicator | EEX | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.25 | 38.41 |
| Support Level | $4.47 | $7.83 |
| Resistance Level | $5.16 | $9.28 |
| Average True Range (ATR) | 0.23 | 0.53 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 88.46 | 3.79 |
Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. The Majority of the revenue for the company is generated from its Connections segment.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.